[Lipid anomalies in NIDDM and insulin resistance. Role of metformin].
Isnard
F
F
Département de Recherche Clinique, Groupe LIPHA, Suresnes.
André
P
P
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000209:etiology*; D007333:Insulin Resistance; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D008687:Metformin
Anomalies lipidiques dans le DNID et l'insulino-résistance. Rôle de la metformine.